OncoMatch/Clinical Trials/NCT05029063
Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters
Is NCT05029063 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Rivaroxaban 10 MG for venous thromboembolism.
Treatment: Rivaroxaban 10 MG — The purpose of the full trial is to determine the efficacy and safety of prophylactic dose rivaroxaban to prevent VTE among cancer patients with CVC.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Blood counts
No known thrombocytopenia (platelet count < 50x 10^9/L) in the previous 3 months
Kidney function
No severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months)
Liver function
No documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months
Severe renal insufficiency (Creatinine clearance <30 mL/min (defined by Cockcroft-Gault) in the previous 3 months); Documented severe liver disease (e.g., acute clinical hepatitis, chronic active hepatitis or cirrhosis) in the previous 3 months; Known thrombocytopenia (platelet count < 50x 10^9/L) in the previous 3 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify